Deregulation of the IL-23/IL-17 pathway is associated with bladder urothelial carcinoma risk because IL-23R is a critical component of the T-helper 17 cell-mediated inflammatory process that orchestrates inflammation, thereby promoting tumor growth [143]. Here, IL23R is linked to neoplasm.